Scarica l'app Stockscreener
569.17
1.26%
-7.25
Dopo l'orario di chiusura:
570.00
0.83
+0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
FDA Announces Fast-Track Reviews for Nine Drugs in New Program - Bloomberg.com
US FDA announces recipients of national priority vouchers - Reuters
Using data filters to optimize entry into Regeneron Pharmaceuticals Inc.Rate Cut & High Accuracy Trade Signal Alerts - newser.com
Will breakout in Regeneron Pharmaceuticals Inc. lead to full recoveryJuly 2025 Trade Ideas & Capital Efficient Trading Techniques - newser.com
Lipodystrophy Pipeline 2025: Pioneering Clinical - openPR.com
3 Stocks to Buy and Hold Ahead of Upcoming Earnings - Investing.com
Single Ventricle Heart Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Mezzion Pharma, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma - Barchart.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Bellecapital International Ltd. - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Aware Super Pty Ltd as trustee of Aware Super - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Generali Asset Management SPA SGR - MarketBeat
Moran Wealth Management LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals’ Stock Is Climbing Premarket Today - MSN
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised) - Zacks Investment Research
Regeneron Pharmaceuticals (REGN): Assessing Value Following Recent Modest Share Price Gains - simplywall.st
Detecting support and resistance levels for Regeneron Pharmaceuticals Inc.Portfolio Value Summary & AI Forecasted Stock Moves - newser.com
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Morningstar
Regeneron to present new data on Libtayo dosing regimen at ESMO By Investing.com - Investing.com South Africa
Regeneron to present new data on Libtayo dosing regimen at ESMO - Investing.com India
Regeneron Pharmaceuticals Announces New Oncology Data Presentations at ESMO 2025 Meeting - Quiver Quantitative
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers - The Manila Times
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by TD Asset Management Inc - MarketBeat
US Bancorp DE Sells 858 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge - MSN
How sentiment analysis helps forecast Regeneron Pharmaceuticals Inc.Dividend Hike & Weekly Breakout Watchlists - newser.com
Regeneron Pharmaceuticals Shapes Nasdaq Futures with Market Impact - Kalkine Media
Regeneron’s Q3 2025 Earnings: What To Expect - Barchart.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
2 Stocks Down 17% and 21% to Buy Right Now - Yahoo Finance
Regeneron, Scholar Rock Approvals In Limbo As FDA Hits Novo Plant - insights.citeline.com
AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance - Yahoo Finance
Canaccord Genuity reiterates Buy rating on Regeneron stock despite EYLEA headwinds - Investing.com
Morningstar Investment Management LLC Makes New $608,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA approves Celltrion's Eylea bisoimilar - Eyes On Eyecare
Hudson Capital Management LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Vanguard Personalized Indexing Management LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Top chart patterns to watch in Regeneron Pharmaceuticals Inc.Bull Run & Real-Time Volume Spike Alerts - newser.com
Is Regeneron Pharmaceuticals Inc. (RGO) stock ideal for retirement investorsFed Meeting & Weekly High Return Stock Forecasts - newser.com
Predicting Regeneron Pharmaceuticals Inc. trend using moving averagesWeekly Profit Summary & Consistent Return Investment Signals - newser.com
Regeneron’s Gene Therapy DB-OTO Improves Speech Perception in Children With Otoferlin-Related Hearing Loss - CGTLive®
Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss - Benzinga
Citigroup Maintains "Buy" Rating on REGN, Raises Price Target to $660 | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Why Are Regeneron And Scholar Rock Shares Falling On Monday? - Stocktwits
Regeneron plans FDA filing based on latest DB-OTO data - The Pharma Letter
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down on Analyst Downgrade - MarketBeat
Regeneron PharmaceuticalsDB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss - MarketScreener
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss - TradingView
Regeneron Readies FDA Run for Hearing Loss Gene Therapy That Could 'Transform Patients’ Lives' - BioSpace
Cell And Gene Therapy For Multiple Myeloma Market Positioned - openPR.com
Biosimilar Fights Regeneron Bid To Block Eye Treatment - Law360
A New Gene Therapy for Deafness Looks Promising - Bloomberg.com
Cwm LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (REGN) Stock Analysis: A 27.79% Upside Beckons Investors Amidst Biotechnology Innovations - DirectorsTalk Interviews
Cantor Fitzgerald Brokers Raise Earnings Estimates for REGN - MarketBeat
Regeneron (REGN) Gene Therapy Shows Promising Results for Geneti - GuruFocus
How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise? - Yahoo Finance
Regeneron Pharma Reports Promising Results For DB-OTO Gene Therapy In Genetic Hearing Loss - Nasdaq
Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy - BioPharma Dive
Regeneron Pharmaceuticals, Inc. Announces Updated Data for Their Investigational Gene Therapy Db-Oto for Profound Genetic Hearing Loss - MarketScreener
GW Henssler & Associates Ltd. Raises Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
2.30%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):